Company intelligence / Profile preview

FeRx

San Diego, California, United Statescbinsights.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

FeRx developed a magnetic nanoparticle-based drug delivery system designed to deliver chemotherapy directly to tumors using an external magnet. Its lead product, MTC-doxorubicin ("MTC‑DOX"), received orphan drug designation for primary liver cancer but failed to show sufficient benefit in Phase 2 trials and was discontinued. The company ceased operations after failing to secure additional funding following disappointing clinical results[3].

Therapeutic areas: Oncology
Modalities: Small moleculeNanoparticle (specifically, magnetic targeted carrier microparticles)Biologic (potential platform use)Gene therapy vector (potential platform use)
Industry: Biotech

Drug pipeline

1 asset

MTC-doxorubicin

Beyond the preview

Go deeper on FeRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FeRx.

Explore the full profile